Kiniksa Pharmaceuticals International, plc 8-K

What Happened
Kiniksa Pharmaceuticals International, plc (KNSA) filed an 8-K on May 1, 2026 reporting that Eben Tessari informed the company on April 30, 2026 that he will resign as Chief Strategy Officer to pursue another life sciences executive role. Mr. Tessari’s resignation is effective May 15, 2026. He will immediately become a consultant to Kiniksa and serve as a special advisor to its Science and Research Committee under a Consulting Agreement effective May 15, 2026.

Key Details

• Resignation notice given April 30, 2026; effective May 15, 2026.
• Consulting Agreement term: May 15, 2026 to May 15, 2027, with an option to renew for one additional year by mutual agreement.
• Compensation under the Consulting Agreement: $450 per hour, capped at 20 hours per month (up to $9,000/month; up to $108,000/year if fully used), plus reimbursement for pre‑approved travel and out‑of‑pocket expenses.
• Company states the resignation was not due to any disagreement with the company’s operations, policies, or practices.

Why It Matters
This is an executive-level departure (Item 5.02 disclosure) paired with a consulting arrangement designed to preserve Tessari’s strategic and scientific expertise for Kiniksa. The financial impact appears limited and capped (hourly rate and monthly hours), so direct cost to the company is modest. For investors, the arrangement signals continuity of access to Tessari’s knowledge while he transitions roles, and the disclosure confirms the change was not due to any dispute with management.